TONIX PHARMACEUTICALS HOLDIN (TNXP)
US8902608541 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 24.95M | 120.20M | 178.70M | 77.10M | 11.20M | |||
| Marketable Securities | N/A | N/A | N/A | N/A | N/A | |||
| Inventories | 13.64M | N/A | N/A | N/A | N/A | |||
| Other Current Assets | 9.18M | 10.50M | 10.40M | 10.90M | 2.70M | |||
| Total Current Assets | 47.77M | 130.80M | 189.00M | 88.00M | 13.90M | |||
| Non-Current Assets | ||||||||
| PPE Net | 94.85M | 94.50M | 51.50M | 9.80M | 400.00K | |||
| Goodwill | 965.00K | N/A | N/A | N/A | N/A | |||
| Intangibles | 9.74M | N/A | 100.00K | 100.00K | 100.00K | |||
| Other Non-Current Assets | 1.13M | 400.00K | 300.00K | 200.00K | 100.00K | |||
| Total Non-Current Assets | 106.69M | 94.90M | 51.90M | 10.20M | 700.00K | |||
| TOTAL ASSETS | 154.46M | 225.70M | 240.90M | 98.20M | 14.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 2.35M | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 5.37M | 6.20M | 4.90M | 2.60M | 1.00M | |||
| Accounts Payable | 3.78M | 8.10M | 13.30M | 4.60M | 3.10M | |||
| Other Current Liabilities | 7.38M | 3.90M | 3.50M | 2.60M | 1.00M | |||
| Total Current Liabilities | 18.88M | 18.20M | 21.70M | 9.80M | 5.10M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 6.56M | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 23.49M | 300.00K | 500.00K | 700.00K | 0.00 | |||
| Total Non-Current Liabilities | 30.05M | 300.00K | 500.00K | 700.00K | 0.00 | |||
| TOTAL LIABILITIES | 48.93M | 18.50M | 22.20M | 10.50M | 5.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -600.66M | -470.00M | -359.80M | -267.50M | -217.10M | |||
| Additional Paid In Capital | 706.36M | 677.30M | 578.10M | 355.00M | 226.50M | |||
| Common Shares | 59.00K | 100.00K | 500.00K | 200.00K | 0.00 | |||
| Other Shareholders' Equity | -232.00K | -200.00K | -100.00K | -100.00K | 0.00 | |||
| Shares Outstanding | 58.61M | 12.20M | 2.50M | 1.00M | 0.00 | |||
| Tangible Book Value per Share | 1.62 | 16.98 | 87.44 | 87.50 | 1.09 | |||
| Total Shareholders' Equity | 105.53M | 207.20M | 218.70M | 87.60M | 9.40M | |||
| TOTAL LIABILITIES AND EQUITY | 154.46M | 225.70M | 240.90M | 98.20M | 14.60M | |||
| Statistics | ||||||||
| Debt/Equity | 0.06 | N/A | N/A | N/A | N/A | |||
| Current Ratio | 2.53 | 7.19 | 8.71 | 8.98 | 2.73 | |||
| Return On Assets (ROA) | -75.53% | -51.79% | -38.31% | -53.13% | -212.95% | |||
| Return On Equity (ROE) | -110.55% | -56.41% | -42.20% | -59.55% | -330.74% | |||
All data in USD